– Achieved Global Recognition in Addition to Certifications in Four Regions and 38 … Business Wire India
– Achieved Global Recognition in Addition to Certifications in Four Regions and 38 Countries
– Top Employers Institute® Certification Demonstrates Takeda’s Commitment to its People
Takeda Pharmaceutical Company Limited(TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top Employer® certification for 2021. In addition to receiving the global certification for the fourth consecutive year, Takeda was also certified as a Top Employer in four regions and 38 countries. This underscores the company’s commitment to creating an exceptional people experience for its global workforce.
For more than 30 years, Top Employers Institute has given annual award certification to companies with outstanding culture, work environments, benefits and opportunities for their people. The Institute certifies organizations based on the results of its HR Best Practices Survey. The survey covers 20 people-centric topic areas, including Career Development, Culture, Diversity & Inclusion, Learning, Sustainability, Values, Well-being and Work Environment.
“We are very proud of the global, regional and country recognition we’ve received from Top Employer Institute, especially during a year that fundamentally shifted workforce and workplace paradigms,” said Padma Thiruvengadam, Takeda’s chief human resources officer. “Now more than ever, we are focused on building a learning organization where colleagues from diverse backgrounds, cultures and perspectives are encouraged to use their unique skills to fulfill their career aspirations and help create better health for people and a brighter future for the world.”
Top Employers Institute CEO David Plink commented, “Takeda continues to show its dedication to its employees globally and locally, and we congratulate them for the fourth year in a row of global Top Employer certification.”
Takeda excelled globally in the areas of Values, Ethics & Integrity, Organizational Change, Leadership, Sustainability, Performance Management and Engagement. Each of the 38 Takeda countries that participated in the Top Employer survey received certification, with eight countries receiving certification for the first time. The full list of regions and countries where Takeda was named a Top Employer is below:
- Africa: Algeria
- Asia Pacific: Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand
- Europe: Austria, Finland, France, Germany, Ireland, Italy, Kazakhstan, Poland, Portugal, Russia, Spain, Switzerland, Turkey, UK, and Ukraine
- Latin America: Argentina, Brazil, Colombia, Ecuador, Mexico and Peru
- Middle East: Israel, Saudi Arabia, and United Arab Emirates
- North America: United States
To learn more about Top Employers Institute and the Top Employers certification, please visit: https://www.top-employers.com.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries. For more information, visit https://www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This feed is automatically published via businesswireindia.com